Molecular Characterization of New FBXL4 Mutations in Patients With mtDNA Depletion Syndrome

Encephalomyopathic mitochondrial DNA (mtDNA) depletion syndrome 13 (MTDPS13) is a rare genetic disorder caused by defects in F-box leucine-rich repeat protein 4 (FBXL4). Although FBXL4 is essential for the bioenergetic homeostasis of the cell, the precise role of the protein remains unknown. In this...

Full description

Bibliographic Details
Main Authors: Sonia Emperador, Nuria Garrido-Pérez, Javier Amezcua-Gil, Paula Gaudó, Julio Alberto Andrés-Sanz, Delia Yubero, Ana Fernández-Marmiesse, Maria M. O’Callaghan, Juan D. Ortigoza-Escobar, Marti Iriondo, Eduardo Ruiz-Pesini, Angels García-Cazorla, Mercedes Gil-Campos, Rafael Artuch, Julio Montoya, María Pilar Bayona-Bafaluy
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-01-01
Series:Frontiers in Genetics
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fgene.2019.01300/full
id doaj-3d23431fa04641679dcfda334d4bd917
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Sonia Emperador
Sonia Emperador
Sonia Emperador
Nuria Garrido-Pérez
Nuria Garrido-Pérez
Nuria Garrido-Pérez
Javier Amezcua-Gil
Paula Gaudó
Julio Alberto Andrés-Sanz
Delia Yubero
Delia Yubero
Ana Fernández-Marmiesse
Maria M. O’Callaghan
Maria M. O’Callaghan
Juan D. Ortigoza-Escobar
Juan D. Ortigoza-Escobar
Marti Iriondo
Marti Iriondo
Eduardo Ruiz-Pesini
Eduardo Ruiz-Pesini
Eduardo Ruiz-Pesini
Eduardo Ruiz-Pesini
Angels García-Cazorla
Angels García-Cazorla
Mercedes Gil-Campos
Mercedes Gil-Campos
Rafael Artuch
Rafael Artuch
Julio Montoya
Julio Montoya
Julio Montoya
María Pilar Bayona-Bafaluy
María Pilar Bayona-Bafaluy
María Pilar Bayona-Bafaluy
spellingShingle Sonia Emperador
Sonia Emperador
Sonia Emperador
Nuria Garrido-Pérez
Nuria Garrido-Pérez
Nuria Garrido-Pérez
Javier Amezcua-Gil
Paula Gaudó
Julio Alberto Andrés-Sanz
Delia Yubero
Delia Yubero
Ana Fernández-Marmiesse
Maria M. O’Callaghan
Maria M. O’Callaghan
Juan D. Ortigoza-Escobar
Juan D. Ortigoza-Escobar
Marti Iriondo
Marti Iriondo
Eduardo Ruiz-Pesini
Eduardo Ruiz-Pesini
Eduardo Ruiz-Pesini
Eduardo Ruiz-Pesini
Angels García-Cazorla
Angels García-Cazorla
Mercedes Gil-Campos
Mercedes Gil-Campos
Rafael Artuch
Rafael Artuch
Julio Montoya
Julio Montoya
Julio Montoya
María Pilar Bayona-Bafaluy
María Pilar Bayona-Bafaluy
María Pilar Bayona-Bafaluy
Molecular Characterization of New FBXL4 Mutations in Patients With mtDNA Depletion Syndrome
Frontiers in Genetics
mitochondrial disease
encephalomyopathic mtDNA depletion syndrome 13
F-box leucine-rich repeat protein 4
mitochondrial DNA
mtDNA depletion
mtDNA transcription
author_facet Sonia Emperador
Sonia Emperador
Sonia Emperador
Nuria Garrido-Pérez
Nuria Garrido-Pérez
Nuria Garrido-Pérez
Javier Amezcua-Gil
Paula Gaudó
Julio Alberto Andrés-Sanz
Delia Yubero
Delia Yubero
Ana Fernández-Marmiesse
Maria M. O’Callaghan
Maria M. O’Callaghan
Juan D. Ortigoza-Escobar
Juan D. Ortigoza-Escobar
Marti Iriondo
Marti Iriondo
Eduardo Ruiz-Pesini
Eduardo Ruiz-Pesini
Eduardo Ruiz-Pesini
Eduardo Ruiz-Pesini
Angels García-Cazorla
Angels García-Cazorla
Mercedes Gil-Campos
Mercedes Gil-Campos
Rafael Artuch
Rafael Artuch
Julio Montoya
Julio Montoya
Julio Montoya
María Pilar Bayona-Bafaluy
María Pilar Bayona-Bafaluy
María Pilar Bayona-Bafaluy
author_sort Sonia Emperador
title Molecular Characterization of New FBXL4 Mutations in Patients With mtDNA Depletion Syndrome
title_short Molecular Characterization of New FBXL4 Mutations in Patients With mtDNA Depletion Syndrome
title_full Molecular Characterization of New FBXL4 Mutations in Patients With mtDNA Depletion Syndrome
title_fullStr Molecular Characterization of New FBXL4 Mutations in Patients With mtDNA Depletion Syndrome
title_full_unstemmed Molecular Characterization of New FBXL4 Mutations in Patients With mtDNA Depletion Syndrome
title_sort molecular characterization of new fbxl4 mutations in patients with mtdna depletion syndrome
publisher Frontiers Media S.A.
series Frontiers in Genetics
issn 1664-8021
publishDate 2020-01-01
description Encephalomyopathic mitochondrial DNA (mtDNA) depletion syndrome 13 (MTDPS13) is a rare genetic disorder caused by defects in F-box leucine-rich repeat protein 4 (FBXL4). Although FBXL4 is essential for the bioenergetic homeostasis of the cell, the precise role of the protein remains unknown. In this study, we report two cases of unrelated patients presenting in the neonatal period with hyperlactacidemia and generalized hypotonia. Severe mtDNA depletion was detected in muscle biopsy in both patients. Genetic analysis showed one patient as having in compound heterozygosis a splice site variant c.858+5G>C and a missense variant c.1510T>C (p.Cys504Arg) in FBXL4. The second patient harbored a frameshift novel variant c.851delC (p.Pro284LeufsTer7) in homozygosis. To validate the pathogenicity of these variants, molecular and biochemical analyses were performed using skin-derived fibroblasts. We observed that the mtDNA depletion was less severe in fibroblasts than in muscle. Interestingly, the cells harboring a nonsense variant in homozygosis showed normal mtDNA copy number. Both patient fibroblasts, however, demonstrated reduced mitochondrial transcript quantity leading to diminished steady state levels of respiratory complex subunits, decreased respiratory complex IV (CIV) activity, and finally, low mitochondrial ATP levels. Both patients also revealed citrate synthase deficiency. Genetic complementation assays established that the deficient phenotype was rescued by the canonical version of FBXL4, confirming the pathological nature of the variants. Further analysis of fibroblasts allowed to establish that increased mitochondrial mass, mitochondrial fragmentation, and augmented autophagy are associated with FBXL4 deficiency in cells, but are probably secondary to a primary metabolic defect affecting oxidative phosphorylation.
topic mitochondrial disease
encephalomyopathic mtDNA depletion syndrome 13
F-box leucine-rich repeat protein 4
mitochondrial DNA
mtDNA depletion
mtDNA transcription
url https://www.frontiersin.org/article/10.3389/fgene.2019.01300/full
work_keys_str_mv AT soniaemperador molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT soniaemperador molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT soniaemperador molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT nuriagarridoperez molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT nuriagarridoperez molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT nuriagarridoperez molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT javieramezcuagil molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT paulagaudo molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT julioalbertoandressanz molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT deliayubero molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT deliayubero molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT anafernandezmarmiesse molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT mariamocallaghan molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT mariamocallaghan molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT juandortigozaescobar molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT juandortigozaescobar molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT martiiriondo molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT martiiriondo molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT eduardoruizpesini molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT eduardoruizpesini molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT eduardoruizpesini molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT eduardoruizpesini molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT angelsgarciacazorla molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT angelsgarciacazorla molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT mercedesgilcampos molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT mercedesgilcampos molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT rafaelartuch molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT rafaelartuch molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT juliomontoya molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT juliomontoya molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT juliomontoya molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT mariapilarbayonabafaluy molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT mariapilarbayonabafaluy molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
AT mariapilarbayonabafaluy molecularcharacterizationofnewfbxl4mutationsinpatientswithmtdnadepletionsyndrome
_version_ 1724945947391164416
spelling doaj-3d23431fa04641679dcfda334d4bd9172020-11-25T02:03:46ZengFrontiers Media S.A.Frontiers in Genetics1664-80212020-01-011010.3389/fgene.2019.01300489485Molecular Characterization of New FBXL4 Mutations in Patients With mtDNA Depletion SyndromeSonia Emperador0Sonia Emperador1Sonia Emperador2Nuria Garrido-Pérez3Nuria Garrido-Pérez4Nuria Garrido-Pérez5Javier Amezcua-Gil6Paula Gaudó7Julio Alberto Andrés-Sanz8Delia Yubero9Delia Yubero10Ana Fernández-Marmiesse11Maria M. O’Callaghan12Maria M. O’Callaghan13Juan D. Ortigoza-Escobar14Juan D. Ortigoza-Escobar15Marti Iriondo16Marti Iriondo17Eduardo Ruiz-Pesini18Eduardo Ruiz-Pesini19Eduardo Ruiz-Pesini20Eduardo Ruiz-Pesini21Angels García-Cazorla22Angels García-Cazorla23Mercedes Gil-Campos24Mercedes Gil-Campos25Rafael Artuch26Rafael Artuch27Julio Montoya28Julio Montoya29Julio Montoya30María Pilar Bayona-Bafaluy31María Pilar Bayona-Bafaluy32María Pilar Bayona-Bafaluy33Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, SpainInstituto de Investigación Sanitaria de Aragón (IIS-Aragón), Zaragoza, SpainFundación ARAID, Universidad de Zaragoza, Zaragoza, SpainDepartamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, SpainInstituto de Investigación Sanitaria de Aragón (IIS-Aragón), Zaragoza, SpainFundación ARAID, Universidad de Zaragoza, Zaragoza, SpainDepartamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, SpainDepartamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, SpainDepartamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, SpainClinical Biochemistry, Genetics, Pediatric Neurology and Neonatalogy Departments, Institut de Recerca Sant Joan de Déu, Barcelona, SpainCentro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, SpainGenomes&Disease Group, Molecular Medicine and Chronic Diseases Research Centre (CiMUS), Santiago de Compostela University—IDIS, Santiago de Compostela, SpainClinical Biochemistry, Genetics, Pediatric Neurology and Neonatalogy Departments, Institut de Recerca Sant Joan de Déu, Barcelona, SpainCentro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, SpainClinical Biochemistry, Genetics, Pediatric Neurology and Neonatalogy Departments, Institut de Recerca Sant Joan de Déu, Barcelona, SpainCentro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, SpainClinical Biochemistry, Genetics, Pediatric Neurology and Neonatalogy Departments, Institut de Recerca Sant Joan de Déu, Barcelona, SpainCentro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, SpainDepartamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, SpainInstituto de Investigación Sanitaria de Aragón (IIS-Aragón), Zaragoza, SpainFundación ARAID, Universidad de Zaragoza, Zaragoza, SpainCentro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, SpainClinical Biochemistry, Genetics, Pediatric Neurology and Neonatalogy Departments, Institut de Recerca Sant Joan de Déu, Barcelona, SpainCentro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, SpainMetabolism Unit, Reina Sofia University Clinical Hospital, Institute Maimónides of Biomedicine Investigation of Córdoba (IMIBIC), University of Córdoba, Córdoba, SpainCIBEROBN (Physiopathology of Obesity and Nutrition CB12/03/30038), Madrid, SpainClinical Biochemistry, Genetics, Pediatric Neurology and Neonatalogy Departments, Institut de Recerca Sant Joan de Déu, Barcelona, SpainCentro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, SpainDepartamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, SpainInstituto de Investigación Sanitaria de Aragón (IIS-Aragón), Zaragoza, SpainCentro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, SpainDepartamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, SpainInstituto de Investigación Sanitaria de Aragón (IIS-Aragón), Zaragoza, SpainCentro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, SpainEncephalomyopathic mitochondrial DNA (mtDNA) depletion syndrome 13 (MTDPS13) is a rare genetic disorder caused by defects in F-box leucine-rich repeat protein 4 (FBXL4). Although FBXL4 is essential for the bioenergetic homeostasis of the cell, the precise role of the protein remains unknown. In this study, we report two cases of unrelated patients presenting in the neonatal period with hyperlactacidemia and generalized hypotonia. Severe mtDNA depletion was detected in muscle biopsy in both patients. Genetic analysis showed one patient as having in compound heterozygosis a splice site variant c.858+5G>C and a missense variant c.1510T>C (p.Cys504Arg) in FBXL4. The second patient harbored a frameshift novel variant c.851delC (p.Pro284LeufsTer7) in homozygosis. To validate the pathogenicity of these variants, molecular and biochemical analyses were performed using skin-derived fibroblasts. We observed that the mtDNA depletion was less severe in fibroblasts than in muscle. Interestingly, the cells harboring a nonsense variant in homozygosis showed normal mtDNA copy number. Both patient fibroblasts, however, demonstrated reduced mitochondrial transcript quantity leading to diminished steady state levels of respiratory complex subunits, decreased respiratory complex IV (CIV) activity, and finally, low mitochondrial ATP levels. Both patients also revealed citrate synthase deficiency. Genetic complementation assays established that the deficient phenotype was rescued by the canonical version of FBXL4, confirming the pathological nature of the variants. Further analysis of fibroblasts allowed to establish that increased mitochondrial mass, mitochondrial fragmentation, and augmented autophagy are associated with FBXL4 deficiency in cells, but are probably secondary to a primary metabolic defect affecting oxidative phosphorylation.https://www.frontiersin.org/article/10.3389/fgene.2019.01300/fullmitochondrial diseaseencephalomyopathic mtDNA depletion syndrome 13F-box leucine-rich repeat protein 4mitochondrial DNAmtDNA depletionmtDNA transcription